COVCLEO DIAGNOSTICS LTD
Announcement history available from 1 August 2025
Fromto
| Date / Time | Title | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 21 Aug 2026, 02:01 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 21 Aug 2026, 01:52 | Appendix 4E and 2026 Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 29 July 2026, 19:39 | Quarterly activities and cashflow report | Quarterly Reports | MS | 19004, 19009 | |
| 13 July 2026, 19:10 | CLEO Enters Analytical Validation Phase | Company Update | MS | 11001 | |
| 8 July 2026, 02:41 | Change in Director's Interest Notice | Director Interests | — | 02009 | |
| 29 May 2026, 02:18 | Cleansing Notice | Securities Administration | — | 06018 | |
| 29 May 2026, 02:12 | Application for quotation of securities - COV | Other | — | 06020 | |
| 20 May 2026, 19:25 | CLEO Establishes U.S. Reimbursement Pathway | Company Update | MS | 11001 | |
| 29 Apr 2026, 19:32 | Quarterly activities and cashflow report | Quarterly Reports | MS | 19003, 19008 | |
| 28 Apr 2026, 18:26 | CLEO Commences Kit Manufacturing Ahead of FDA Submission | Company Update | MS | 11001 | |
| 31 Mar 2026, 20:04 | Sample Collection Completion for Pivotal US Clinical Trial | Company Update | MS | 11001 | |
| 23 Mar 2026, 19:29 | CLEO Optimises Biomarker Panel Ahead of FDA Submission | Company Update | MS | 11001 | |
| 26 Feb 2026, 03:24 | Appendix 4D and Half Yearly Accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 18 Feb 2026, 20:44 | CLEO Confirms Next-Gen Platform for Ovarian Cancer Test | Company Update | MS | 11001 | |
| 29 Jan 2026, 19:24 | Quarterly activities and cashflow report | Quarterly Reports | MS | 19002, 19007 | |
| 6 Jan 2026, 02:26 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 29 Dec 2025, 22:23 | Chairman's End of Year Letter to Shareholders | Letters & Addresses | — | 16002 | |
| 29 Dec 2025, 22:16 | Cleansing Notice | Securities Administration | — | 06018 | |
| 29 Dec 2025, 22:11 | Notification regarding unquoted securities - COV | Other | — | 06021 | |
| 29 Dec 2025, 22:06 | Application for quotation of securities - COV | Other | — | 06020 | |
| 29 Dec 2025, 22:04 | Application for quotation of securities - COV | Other | — | 06020 | |
| 18 Dec 2025, 20:54 | Proposed issue of securities - COV | Securities Administration | — | 06013 | |
| 18 Dec 2025, 20:53 | CLEO Raises $5m to Support U.S. Market Launch | Capital Raising | MS | 06003, 09014 | |
| 17 Dec 2025, 19:50 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 29 Nov 2025, 03:31 | Notice under Listing Rule 3.10A | Securities Administration | — | 06009 | |
| 26 Nov 2025, 19:25 | Cleo Strengthens Cash Position with $1.7m R&D Tax Refund | Periodic Reports | MS | 03014 | |
| 25 Nov 2025, 01:40 | Results of Annual General Meeting | Meetings & Governance | — | 08003 | |
| 19 Nov 2025, 21:02 | CLEO Appoints First Key Opinion Leader to Support US Market | Company Administration | MS | 12008 | |
| 6 Nov 2025, 20:19 | CLEO Significantly Expands Addressable Market | Company Update | MS | 11001 | |
| 1 Nov 2025, 01:39 | Quarterly activities and cashflow report | Quarterly Reports | MS | 19001, 19006 | |
| 30 Oct 2025, 20:44 | CLEO Successfully Completes Stage 1 MDSAP Audit | Company Update | MS | 11001 | |
| 26 Sept 2025, 02:28 | Letter to Shareholders | Meetings & Governance | — | 08001, 16002 | |
| 26 Sept 2025, 02:14 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 | |
| 20 Sept 2025, 02:33 | Application for quotation of securities - COV | Other | — | 06020 | |
| 15 Sept 2025, 19:30 | Cleo Receives Positive FDA Feedback | Company Update | MS | 11001 | |
| 6 Sept 2025, 02:34 | Notice Required Under ASX Listing Rule 3.13.1 | Meetings & Governance | — | 08006, 12008 | |
| 27 Aug 2025, 02:55 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 27 Aug 2025, 02:48 | Appendix 4E and 2025 Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 18 Aug 2025, 19:22 | COV Commences Health Economic Study-Support US Market Entry | Company Update | MS | 11001 | |
| 16 Aug 2025, 02:24 | Restricted securities to be released from escrow | Securities Administration | — | 06009 |
1–40 of 40
1 / 1